Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of JY028 for neovascular age-related macular degeneration
CTR20221676Phase 2Active
- Sponsor
- Beijing Eastern Biotech
- Start
- Sep 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JHL1149 in exudative macular degeneration, sponsored by Beijing Eastern Biotech. Started Sep 2022; status: active.
02
Drugs
JHL1149
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20221676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221676.